CClinicalTrials.gg
TerminatedNCT00967837woundsUpdated Aug 10, 2016

Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics

A Phase 2/3 interventional study of Pulsatile Intravenous Insulin Therapy in Wound Healing and Diabetes, sponsored by Florida Atlantic University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-10.

Sponsored by Florida Atlantic University · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Administrative
Phase
Phase 2/3
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

One of the significant complications associated with some patients with diabetes is the inability for wounds to heal regardless of enrolling and participating in a traditional wound healing program. There have been a number of anecdotal evidence presented by patients receiving pulsatile intravenous insulin therapy for other complications with non healing wounds lasting from several months to several years whose wounds healed while receiving therapy. This study was designed to specifically monitor the progress of diabetic patients who have failed traditional wound care therapy and monitor the progress of their wounds while receiving pulsatile intravenous insulin therapy.

Read the detailed description

Diabetes can produce complications including the inability for wounds to heal despite participating in a traditional wound care therapy program.

At times of reduced tissue oxygen, such as when circulation is decreased, there is anecdotal evidence that pulsed IV insulin (by enabling the production of energy from glucose) may permit heart, skeletal muscle, skin, and other organs to function more normally and even to repair damage and heal. By tracking the progress in diabetic patients that have failed traditional wound care therapy who are monitored by their podiatrist or other health care professional to objectively determine the effect of pulsatile IV therapy on the rate of healing.

Independent evaluation of the wound is provided including visual examination, pictures and measurements on a weekly to bi-weekly basis.

Individuals breathe into a mask for 3-5 minutes after a rest period of 30 or more minutes. The ratio of exhaled volume of CO2 to the inhaled volume of O2 is determined as the RQ. The physiologic range is 0.7 to1.3. Individuals using fat as a primary fuel have a ratio of 0.7, protein or mixed fuels is 0.8-0.9 and carbohydrate is 0.9-1.0. Those taking excessive calories will have RQ's higher than 1.05. The RQ can be followed serially and this is done before and after each pulsatile IV insulin treatment, during the 3 successive sessions on a single treatment day. The amount of intravenous insulin and oral glucose given is determined by the RQ changes during the previous session. Pulsatile IV insulin therapy encourages the glucose metabolism in diabetics to normalize in multiple organs, especially muscle, retina, liver, kidney and nerve endings. The process fundamentally requires the administration of high dose insulin pulses similar to those found in non diabetic humans by their pancreas into the surrounding portal circulation. Oral carbohydrates are given simultaneously to augment the process and prevent hypoglycemia. The process is monitored by frequent glucose levels and respiratory quotients (RQ). RQ is measured by a metabolic cart which determines the ratio VCO2/ VO2. This ratio is specific for the fuel used at any one time by the body. The glucose levels are monitored to keep glucose levels appropriate and the RQ determines the need to readjust the infusion protocol in each patient for subsequent insulin infusion sessions.Patient is evaluated post session and discharged when stable.

Frequent monitoring of RQ is necessary as these levels change rapidly, depending on the fuel being utilized by the body. Pulsatile IV insulin therapy shifts metabolism from primarily fatty acid metabolism to primarily glucose metabolism. This shift is reflected by the increase in respiratory quotient. However during rest periods the RQ may fall back to lower levels. Therefore RQ's are done at the beginning and at the end of each insulin infusion session of 1 hour in order to appropriately monitor and adjust insulin and carbohydrate loads to reach optimal activation in each session

02

Conditions studied

  • Wound Healing
  • Diabetes

Browse trials for

Keywords

  • Diabetes with complications
  • Wound healing
03

In context

Wounds and Injuries

5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.

This study's enrollment of 152 is above the median of 52 across 3,239 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Florida Atlantic University is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosed with type 1 or type 2 diabetes
  • taking oral and/or insulin for diabetes control
  • endocrinologist must assess and approve pt for participation in study
  • ability to swallow without difficulty
  • ability to meet weekly time and testing requirements for this study

Exclusion criteria

Exclusion Criteria:

  • inability to do testing required for study including regular scheduled visits for independent review of non healing wound including assessment, pictures and measurements
  • lack of intravenous access
  • alcohol abuse, drug addiction or the use of illegal drugs
  • positive HIV
  • active liver disease
  • in active treatment for cancer including radiation or chemotherapy
  • inability to breathe into machine for respiratory quotients to monitor progress
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Diabetes with non healing wounds

    To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds

    Procedure: Pulsatile Intravenous Insulin Therapy

Interventions

  • ProcedurePulsatile Intravenous Insulin Therapy

    Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.

    Also known as: Humulin, Humulin R, Novolog

06

What researchers measure

Primary outcomes

  1. To measure progress of wound healing in subjects that have failed conventional wound care healing treatments for 60 days

    Time frame: Monitoring of wound is done at baseline and weekly follow up visits including visual examination, pictures of wound and measurements

07

Study locations

1 site
  • Florida Atlantic University
    Boca Raton, Florida 33487, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00967837
Lead sponsor
Florida Atlantic University
Collaborators
Advanced Diabetes Treatment Centers
Responsible party
Sponsor
First posted
Aug 28, 2009
Start date
Jan 2006
Primary completion
Jan 2012
Completion
Sep 2012
Last update
Aug 10, 2016

Study contacts

Betty Tuller, PhD
principal investigator · Florida Atlantic University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion